Cantor Fitzgerald Maintains Neutral on Arrowhead Pharmaceuticals, Raises Price Target to $50

Cantor Fitzgerald maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Neutral and raises the price target from $24 to $50.

Benzinga · 11/19/2019 12:46

Cantor Fitzgerald maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Neutral and raises the price target from $24 to $50.